Independence will cover the use of Veklury® (remdesivir), Bamlanivimab® (LY-CoV555), and Casirivimab/Imdevimab for the treatment of Commercial and Medicare Advantage patients who have been diagnosed with COVID-19 and require hospitalization.
The coverage is effective
October 22, 2020, through the later of March 31, 2021, or the duration of the public health emergency.
Independence is committed to providing our members with access to the care they need during the COVID-19 pandemic. We encourage all Independence members and providers to visit our dedicated COVID-19 webpage regularly for the latest news and updates.
We will continue to evaluate member needs as the situation changes.
Read more about the indications for use, coverage, dosage and administration recommendations, and reimbursement in the News Articles posted on our Medical and Claim Payment Policy Portal: